Catalyst Pharmaceuticals Inc to Post Q4 2019 Earnings of $0.00 Per Share, Oppenheimer Forecasts (CPRX)
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) – Oppenheimer cut their Q4 2019 earnings estimates for shares of Catalyst Pharmaceuticals in a research report issued on Thursday, November 8th. Oppenheimer analyst L. Gershell now expects that the biopharmaceutical company will earn $0.00 per share for the quarter, down from their prior forecast of $0.05. Oppenheimer has a “Buy” rating and a $6.00 price target on the stock. Oppenheimer also issued estimates for Catalyst Pharmaceuticals’ FY2022 earnings at $1.28 EPS.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.08) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.08).
Shares of Catalyst Pharmaceuticals stock opened at $2.87 on Monday. Catalyst Pharmaceuticals has a 52 week low of $2.18 and a 52 week high of $4.51.
Several institutional investors have recently made changes to their positions in CPRX. BlackRock Inc. lifted its stake in shares of Catalyst Pharmaceuticals by 29.0% in the 2nd quarter. BlackRock Inc. now owns 6,059,627 shares of the biopharmaceutical company’s stock valued at $18,905,000 after purchasing an additional 1,361,096 shares during the last quarter. Panagora Asset Management Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 120.2% in the 3rd quarter. Panagora Asset Management Inc. now owns 611,450 shares of the biopharmaceutical company’s stock valued at $2,311,000 after buying an additional 333,821 shares during the period. GSA Capital Partners LLP raised its holdings in shares of Catalyst Pharmaceuticals by 295.7% in the 2nd quarter. GSA Capital Partners LLP now owns 380,605 shares of the biopharmaceutical company’s stock valued at $1,187,000 after buying an additional 284,409 shares during the period. Dimensional Fund Advisors LP purchased a new stake in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at $990,000. Finally, Millennium Management LLC raised its holdings in shares of Catalyst Pharmaceuticals by 16.5% in the 2nd quarter. Millennium Management LLC now owns 1,610,176 shares of the biopharmaceutical company’s stock valued at $5,024,000 after buying an additional 227,918 shares during the period. 51.37% of the stock is currently owned by institutional investors and hedge funds.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.
Further Reading: Ex-Dividend
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.